Clinical Trial Update: Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating [123I]MNI-420 with SPECT as a marker of the adenosine A2a receptor in Parkinson disease, Huntington disease, and healthy subjects; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease
• Parkinson Disease

Drugs mentioned

• [123I]MNI-420 (MNI-420)

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Parkinson Disease, Huntington Disease | Phase 1 | Status: COMPLETED